您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > MSDC-0602K
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MSDC-0602K
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
MSDC-0602K图片
CAS NO:1314533-27-1
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
MSDC-0602K (Azemiglitazone potassium) 是一种噻唑烷二酮类化合物,与 PPARγ 结合,IC50 为 18.25 μM。MSDC-0602K 调节线粒体丙酮酸载体 (MPC)。MSDC-0602K 可用于脂肪肝的研究,包括功能失调的脂质代谢、炎症和胰岛素抵抗。MSDC-0602K 是一种胰岛素 (insulin) 增敏剂,单独或与 Liraglutide 联合使用可改善小鼠的胰岛素血症和脂肪肝疾病。
Cas No.1314533-27-1
别名Azemiglitazone potassium
分子式C19H16KNO5S
分子量409.5
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

MSDC-0602K (Azemiglitazone potassium), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM[1]. MSDC-0602K modulates the mitochondrial pyruvate carrier (MPC). MSDC-0602K can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance[2]. MSDC-0602K, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide[3].

Diabetic db/db and MS-NASH mice are treated with MSDC-0602K by oral gavage, Liraglutide by s.c. injection, or combination MSDC-0602K + Liraglutide. This combination treatment may be an effective therapeutic strategy for diabetes and non-alcoholic steatohepatitis (NASH).

[1]. Zhouji Chen, et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48.
[2]. Jerry R Colca, et al. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. Expert Opin Investig Drugs. 2018 Jul;27(7):631-636.
[3]. Dakota R Kamm, et al. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. J Biol Chem. Jan-Jun 2021;296:100807.